Helicobacter pylori-negative Gastric Mucosa-associated Lymphoid Tissue Lymphoma.
10.7704/kjhugr.2017.17.3.122
- Author:
Jin Tae JUNG
1
Author Information
1. Department of Internal medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. jungjt@cu.ac.kr
- Publication Type:Review
- Keywords:
Helicobacter pylori;
Lymphoma;
B-cell;
marginal zone
- MeSH:
B-Lymphocytes;
Drug Therapy;
Helicobacter pylori;
Helicobacter*;
Lymphoid Tissue;
Lymphoma;
Lymphoma, B-Cell, Marginal Zone*;
Prognosis;
Radiotherapy
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2017;17(3):122-126
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Approximately 90% of gastric mucosa-associated lymphoid tissue (MALT) lymphomas are associated with Helicobacter pylori infection and 10% of gastric MALT lymphomas occur independent of H. pylori infection. The gene translocation t(11;18)(q21;q21) is frequently observed in cases presenting with H. pylori-negative gastric MALT lymphomas. H. pylori-negative gastric MALT lymphomas do not differ from H. pylori-positive gastric MALT lymphomas in terms of clinical features and endoscopic findings and show similar prognosis. H. pylori eradication therapy could be considered as first-line treatment for gastric MALT lymphomas regardless of their H. pylori infection status. In cases with H. pylori-negative gastric MALT lymphomas, the rate of response to eradication therapy varies from 0 to 83%. If gastric MALT lymphoma persists for more than a year, secondary treatment with radiotherapy, chemotherapy, and/or surgery should be considered. Of note, the comparative outcome is excellent.
